Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

This company has been moved to the archive! The financial data has not been updated since February 15, 2024.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Vertex Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Accounts payable 1.61 1.67 1.45 1.32 1.05
Product revenue accruals 7.55 7.17 6.31 6.65 7.71
Payroll and benefits 1.30 1.36 1.42 1.44 1.92
Research, development and commercial contract costs 1.17 1.09 1.28 1.16 1.27
Royalty payable 1.05 1.18 1.49 1.41 1.19
Tax related accruals 0.44 0.68 1.57 0.89 0.87
Other 0.18 0.23 0.42 0.40 0.48
Accrued expenses 11.68% 11.72% 12.50% 11.96% 13.43%
Milestone payment due to CRISPR 0.88 0.00 0.00 0.00 0.00
Contract liabilities 0.75 0.88 1.28 1.63 0.75
Current finance lease liabilities 0.22 0.22 0.35 0.36 0.47
Current operating lease liabilities 0.15 0.27 0.25 0.09 0.14
Other 0.32 0.34 0.12 0.62 0.21
Other current liabilities 2.32% 1.72% 2.00% 2.70% 1.57%
Current liabilities 15.61% 15.11% 15.95% 15.98% 16.05%
Long-term finance lease liabilities 1.65 2.37 3.80 4.59 6.47
Long-term operating lease liabilities 1.53 2.09 2.81 2.98 1.01
Tax-related liabilities 3.00 2.49 0.00 0.00 0.00
Contingent consideration 0.34 0.63 1.39 1.61 2.12
Other 0.52 0.65 0.87 0.92 1.19
Other long-term liabilities 3.86% 3.78% 2.26% 2.54% 3.31%
Long-term liabilities 7.05% 8.24% 8.86% 10.10% 10.80%
Total liabilities 22.66% 23.35% 24.81% 26.08% 26.85%
Preferred stock, $0.01 par value; none issued and outstanding 0.00 0.00 0.00 0.00 0.00
Common stock, $0.01 par value 0.01 0.01 0.02 0.02 0.03
Additional paid-in capital 32.77 40.69 51.23 67.17 95.42
Accumulated other comprehensive income (loss) -0.06 0.00 0.12 -0.58 -0.02
Retained earnings (accumulated deficit) 44.62 35.94 23.83 7.31 -22.28
Shareholders’ equity 77.34% 76.65% 75.19% 73.92% 73.15%
Total liabilities and shareholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Vertex Pharmaceuticals Inc. current liabilities as a percentage of total liabilities and shareholders’ equity decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Vertex Pharmaceuticals Inc. long-term liabilities as a percentage of total liabilities and shareholders’ equity decreased from 2021 to 2022 and from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Vertex Pharmaceuticals Inc. total liabilities as a percentage of total liabilities and shareholders’ equity decreased from 2021 to 2022 and from 2022 to 2023.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Vertex Pharmaceuticals Inc. shareholders’ equity as a percentage of total liabilities and shareholders’ equity increased from 2021 to 2022 and from 2022 to 2023.